Search PubMed⌕ Search

Biomedical subjects

K Tainaka

Publications and source records attributed to K Tainaka.

26 records · Page 2Linked to original sources
PubMed1988

[Effects of hyperthermia combined with chemoembolization using degradable starch microspheres in the treatment of hepatocellular carcinoma].

Twenty-eight cases with non-resectable hepatocellular carcinoma were examined. Chemoembolization using degradable starch microspheres (DSM) was performed in 19 cases. DSM, 40-45 micron in diameter, which are degraded by serum amylase, temporarily obstruct arterial blood flow at capillary bed. Adriamycin mixed with DSM was injected into patients through the proper hepatic artery. Hyperthermia (8 MHz radiofrequency) combined with chemoembolization was performed in 9 cases. In all cases treated by hyperthermia combined with chemoembolization, the intratumoral temperature was measured by a thermocouple thermometer during heating alone and heating after injection of DSM. The therapeutic effect was evaluated by the change in tumor size measured by angiography or computed tomography. The efficacy of hyperthermia combined with chemoembolization was compared with that of chemoembolization alone. Intratumoral temperature was 1.0 degree C higher by heating after injection of DSM than by heating alone. Partial response (tumor regression of over 50%) was observed in 8 of 19 cases (42%) with chemoembolization alone. Partial response was observed in 6 of 9 cases (67%) with hyperthermia combined with chemoembolization. One-year survival rate was 58% in chemoembolization alone, against 83% in hyperthermia combined with chemoembolization. Our results suggest that hyperthermia combined with chemoembolization using DSM is effective in the treatment of hepatocellular carcinoma.

Adult↗
PubMed1988

[Chemoembolization and regional hyperthermia with degradable starch microspheres in the treatment of malignant hepatic tumors].

Antitumor effects of chemoembolization with degradable starch microspheres (DSM) combined with regional hyperthermia (HT) were investigated in patients with hepatocellular carcinoma and metastatic liver cancer. Chemoembolization with DSM was performed in 39 cases of hepatocellular carcinoma (HCC) and in 25 cases of metastatic liver cancer. Thirteen cases of HCC and 3 cases of metastatic liver cancer were treated with the combination of HT. A catheter was placed in the proper hepatic artery via the trans-femoral approach. Adriamycin or Mitomycin C mixed with DSM was injected every 2 or 3 weeks through the catheter. Thermotron RF-8, the heating device used in this study, is operated at 8 MHz radiofrequency. Hyperthermia treatment was applied twice a week. The therapeutic effect of this treatment was evaluated by the change in tumor size measured by angiography or computed tomography. Tumor regression over 50% was observed in 42% of the patients with HCC treated with chemoembolization alone and in 54% of those with chemoembolization and HT. In the patients with metastatic liver cancer, tumor regression over 50% was observed in 65% of the patients treated with chemoembolization alone and in 33% of those with chemoembolization and HT. One-year survival rate after the initial treatment in patients with HCC was 66% and 89% in the patients treated with chemoembolization alone and with chemoembolization and HT, respectively. One and two-year survival rates in the patients with metastatic liver cancer was 55% and 41% in the treatment with chemoembolization alone. These results suggest that chemoembolization using DSM was markedly effective in the patients with malignant hepatic tumors, particularly in metastatic liver cancer.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[Chemoembolization with degradable starch microspheres in metastatic liver cancer].

Transcatheter chemoembolization using Degradable Starch Microspheres (DSM) was performed in 22 patients with metastatic liver cancer. DSM, 45 micron in diameter, which are degraded by serum amylase, temporarily obstruct arterial blood flow at the arteriolar capillary bed. Mitomycin C mixed with DSM was injected into the proper hepatic artery. The therapeutic effect of this chemoembolization was evaluated by the change in tumor size measured by angiography or computed tomography. Tumor regression of over 50% was observed in 15 of 22 cases (68%). Elevated serum CEA levels (greater than 10 ng/ml) decreased in 13 of 18 cases (72%). The overall one-year survival rate was 55%. The one-year survival rate was 83% in 8 patients with H2 type liver metastasis. Although half of the patients had transient pain within 2 hours, no major side effects such as bone marrow suppression or hepatotoxicity were observed. Our results suggest that chemoembolization using DSM is effective in the treatment of metastatic liver cancer.

Embolization, Therapeutic↗
PubMed1988

[Radical endoscopic treatment of early gastric cancer-indication for and evaluation of endoscopic resection].

In the endoscopic treatment of early gastric cancer, it is absolutely necessary to adapt a radical approach. The indication for this technique in 545 surgically resected cases of single gastric cancer was studied and technical evaluation was made of endoscopic resection (ER) in 98 of early gastric cancer lesions. Except for 2 special lesions of early gastric cancer, invasion depth m and sm minute invasion [sm(+)] cancer did not show lymph node metastasis [n(+)], but this was recognized in sm(++) cancer showing more than moderate invasion and which was deeper than pm cancers. The applicable lesions were selected excluding the n(+)-risk group with invasion deeper than sm(++) based on histological type, macroscopic type, size and the presence or absence of ulcers(Ul). These were differentiated type II a less than 2 cm in size, differentiated type Ul(-) II c of less than 1 cm and undifferentiated type Ul(-) II c of less than 5 mm in areas excluding the fundic gland mucosa. Our method of ER is endoscopic double snare polypectomy. II a or II c lesion is artificially squeezed into a pedunculated form. The cutting snare is placed over the peduncle, the grasping forceps are replaced with another snare to grasp the tumor firmly. Then cutting snare is applied to include sufficient normal mucosa surrounding the lesion and coagulating current is passed through to slowly resect the ared. The 1st-ER healing ratio, remnant ratio and recurrence ratio of standard ER in 55 II a and 30 II c lesions were 83.5, 12.9 and 3.5% respectively. The recurrent cases were retrospectively found originals in the remnant. Among remnant and recurrences, the 2nd-ER healing ratio was 43% (6/14) and surgically treated cases were 8 (6 inapplicable cases), the final ER healing ratio being 90.6% and satisfactory. Most of the remnant lesions were II a of more than 2 cm, and II c of more than 1 cm for differentiated type and II c for undifferentiated type. As ER could not be applied to these lesions, its indication was confirmed to be technically satisfactory.

Gastroscopy↗
PubMed1987

[Chemoembolization with degradable starch microspheres in malignant hepatic tumors].

A new method of chemoembolization with degradable starch microspheres (DSM) was used for patients with malignant hepatic tumors. DSM, 40-45 micron in diameter, which are degraded by serum amylase, temporarily obstruct arterial blood flow at the arteriolar capillary bed. Experimental studies have demonstrated that such occlusion enhances the regional uptake and reduces systemic exposure to simultaneously administered arterial anticancer drugs. Transcatheter chemoembolization with DSM was performed in 14 cases of hepatocellular carcinoma and 8 cases of metastatic liver cancer. Adriamycin or Mitomycin C mixed with DSM was injected into the patients with hepatocellular carcinoma or metastatic liver cancer, respectively, through the proper hepatic artery. The therapeutic effect of this chemoembolization was evaluated by the change in tumor size measured by angiography or computed tomography. In hepatocellular carcinoma, tumor regression of over 50% was observed in 5 of 14 patients. Elevated serum AFP level of more than 200 ng/ml was decreased in all 6 cases. In metastatic liver cancer, tumor regression of over 50% was observed in 4 of 8 cases. Although half of the patients had transient pain within 2 hours, no major side effects such as bone marrow suppression and hepatotoxicity were observed. Our results suggest that chemoembolization with DSM can be effectively used in the treatment of malignant hepatic tumors.

Carcinoma, Hepatocellular↗